FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
14.1 USD
-0.05 (-0.355%)
INBX Financial Statements
Year
2023
2022
2021
2020
Current Assets
295.36M
280.49M
139.11M
132.17M
Cash & Short Term Investments
277.92M
273.87M
131.3M
128.66M
Cash And Cash Equivalents
277.92M
273.87M
131.3M
128.66M
Short Term Investments
0
0
0
0
Net Receivables
778k
257k
878k
615k
Inventory
0
-257k
-878k
-129.28M
Other Current Assets
366k
181k
7.81M
132.17M
Non-Current Assets
12.54M
10.38M
11.34M
11.57M
Property, Plant & Equipment
9.37M
7.22M
9.49M
11.32M
Goodwill And Intangible Assets
0
0
0
0
Goodwill
0
0
0
0
Intangible Assets
0
0
0
0
Long Term Investments
0
0
0
0
Tax Assets
0
0
0
0
Other Non-Current Assets
3.16M
3.16M
1.85M
245k
Other Assets
0
0
0
0
Total Assets
307.89M
290.88M
150.45M
143.74M
-
-
-
-
Current Liabilities
56.31M
27.58M
22.45M
31.4M
Accounts Payable
8.31M
4.34M
9.13M
13.46M
Short Term Debt
2.06M
1.86M
1.67M
1.5M
Tax Payables
0
0
0
0
Deferred Revenue
0
166k
2.03M
3.08M
Other Current Liabilities
37.37M
15.97M
9.62M
13.36M
Total Current Liabilities
56.31M
27.58M
22.45M
31.4M
Total Non-Current Liabilities
208.08M
205.24M
75.61M
36.87M
Long-Term Debt
206.97M
202.07M
70.47M
35.95M
Deferred Revenue
0
0
110k
737k
Deferred Taxes Liabilities
0
0
-110k
0
Other Non Current liabilities
0
0
5.14M
180k
Total Liabilities
264.39M
232.82M
98.07M
68.27M
Other Liabilities
0
0
0
0
Stockholders Equity
43.5M
58.06M
52.38M
75.47M
Common Stock
5k
4k
4k
4k
Retained Earnings
-613.73M
-372.37M
-227.15M
-145.38M
Accumulated Other Comprehensive Income/Loss
0
0
-150.45M
-143.74M
Other Shareholders Equity
-0
430.43M
279.53M
220.85M
Total Liabilities and Stockholders Equity
307.89M
290.88M
150.45M
143.74M
All figures are in USD.
